<DOC>
	<DOCNO>NCT02257619</DOCNO>
	<brief_summary>The purpose study determine INCB039110 , combination docetaxel , safe effective treatment non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Study INCB039110 Combination With Docetaxel Subjects With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This population consist subject stage IIIB , IV recurrent NSCLC previously treat . The study consist two part , Part 1 Part 2 . Part 1 open label , safety run-in , design confirm safety tolerability INCB039110 combination docetaxel select dose evaluate Part 2 . During Part 1 subject receive open label INCB039110 docetaxel . In Part 2 study , subject randomize receive either INCB039110 placebo docetaxel . The dose frequency INCB039110 docetaxel administer determined Part 1 study . INCB039110/placebo self-administered day entire cycle . This part study conduct double-blind , randomized manner .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis NSCLC Stage IIIb , IV , recurrent . 2 . Received 1 prior systemic chemotherapy regimen Stage IIIb , IV , recurrent disease include neoadjuvant and/or adjuvant therapy . ( NOTE : Exceptions may allow base prior treatment regimen tumor type agreement protocol requirement . ) 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 4 . Life expectancy ≥12 week . 1 . Received prior treatment docetaxel . 2 . Known active central nervous system ( CNS ) metastases . Subjects CNS metastasis complete course therapy would eligible study provide clinically stable least 1 month prior study entry , define : 1 . No evidence new enlarge CNS metastasis new neurological symptom attributable CNS metastasis . 2 . Subjects receive concomitant corticosteroid must stable decrease dose least 4 week prior first dose study treatment anticonvulsant least 4 week prior study entry . 3 . Peripheral neuropathy ≥ Grade 3 . 4 . Current previous malignancy within 2 year study entry , except cure basal squamous cell skin cancer , superficial bladder cancer , prostate intraepithelial neoplasm , carcinoma situ cervix , noninvasive malignancy . 5 . Significant , concurrent , uncontrolled medical condition include limited , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral , psychiatric disease . 6 . Unwilling transfuse blood component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Stage IIIb , IV , Recurrent Non-Small Cell Lung Cancer</keyword>
</DOC>